A phase 2 trial of Coversin in the inflammatory-mediated eye disorder Atopic Keratoconjunctivitis (AKC).

Trial Profile

A phase 2 trial of Coversin in the inflammatory-mediated eye disorder Atopic Keratoconjunctivitis (AKC).

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Coversin (Primary)
  • Indications Keratoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2018 New trial record
    • 06 Feb 2018 According to an Akari Therapeutics media release, the company expects to commence this study in first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top